Clinical Trial Update: Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating olmesartan with chlorthalidone for essential hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• Chlorthalidone (chlorthalidone)
• Olmesartan (olmesartan)

Snippet

Sponsor: EMS | Conditions: Essential Arterial Hypertension | Phase 3 | Status: WITHDRAWN